

References

- Abraham, E. P., and E. Chain. (1940):** An enzyme from bacteria able to destroy penicillin. *Nature* 146:837.
- Afzal-Shah, M., N. Woodford, and D., M. Livermore. (2001):** Characterization of OXA-25, OXA-26, OXA-27, molecular class D β -lactamases associated with carbapenem resistance in clinical isolates of *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 45:583-588.
- Ambler, R. P. (1980):** The structure of β -lactamases. *Phil. Trans. R. Soc. Lond. Biol.* 289:321-331.
- amongst *Enterobacter* species. *J. Antimicrob. Chemother.* 32(Suppl. B):1-11.
- Ann Clin Microbiol Antimicrob. (2004):** Kirby-Bauer disc approximation to detect inducible third-generation cephalosporin resistance in Enterobacteriaceae. Xuan Qin, Scott J Weissman, Mary Frances Chesnut, Bei Zhang, and Lisong Shen. 3: 13.
- Antimicrobial-Drug and Changes in Resistance in *Streptococcus Pneumoniae*, *Emerging Infectious Diseases* Vol.6. No.5 Sep.
- Appelbaum PC. (1992):** Antimicrobial resistance in *Streptococcus pneumoniae* :an overview. *Clin Infect Dis.* 15:77-83.
- Arlet, G., and A. Philippon. (1991):** Construction by polymerase chain reaction and intragenic DNA probes for three main types of transferable β -lactamases (TEM, SHV, CARB). *FEMS Microbiol. Lett.* 82:19-26.
- Arlet, G., G. Brami, Dècrère, A. Flippo, O. Galtolot, P. H. Lagrange, and A. Philippon. (1995):** Molecular characterization by PCR-

restriction fragment length polymorphism of TEM- β -lactamases. FEMS Microbiol. Lett.134:1498-1500.

Bagattini M, Crispino M, Gentile F, Barretta E, Schiavone D, Boccia MC, Triassi M, Zarrilli R. (2004): A nosocomial outbreak of *Serratia marcescens* producing inducible Amp C-type beta-lactamase enzyme and carrying antimicrobial resistance genes within a class 1integron.JHospInfect. Jan;56(1):29-36.

Barroso, H., A. Freitas-Vieira, L. M. Lito, J. M. Cristino, M. J. Salgado, H. F. Neto, J. C. Sousa, G. Soveral, T. Moura, and A. Duarte. (2000): Survey of *Klebsiella Pneumoniae* producing extended-spectrum β -lactamases at a Portuguese hospital: TEM-10 as the endemic enzyme. J. Antimicrob Chemother. 45:611-616.

Barthèlèmy, M., J. Pèduzzi, and R. Labia. (1985): Distinction entre les structures primaires des β -lactamases TEM-1 et TEM-2. Ann. Inst. Pasteur Microbiol. 136A:311-321.

Bates J, Jordens JZ, Griffiths DT. (1994): Fram animals as a putative reservoir for vancomycine-resistant enterococcal infection in man. J Antimicrob Chemother. 34:507-514.

Bauenfeind, A., I. Stemplinger, R. Jungwirth, P.Mangold, S. Amann, E. Akalin, O. Ang, C. Bal, and J. M. Casellas. (1996): Characterization of β -lactamase gene bla_{PER-2}, which encodes an extended-spectrum class A β -lactamase. Antimicrob Agents Chemother.40:616-620.

Bermudes, H., C. Arpin, F. Jude, Z. El-Harrif, C. Bèbèar, and C. Quentin. (1997): Molecular epidemiology of an outbreak due to extended-spectrum β -lactamase-producing enterobacteria in a French hospital. Eur. J. Clin. Microbiol. Infect. Dis. 16:523-529.

- Bethea, JA, Walko, C.M, Targos, P.A (2004):** Treatment of vancomycin-resistant *Enterococcus* with Quinupristin/Dalfopristin and High-Dose Ampicillin. *The Annals of Pharmacotherapy* 38:989-991.
- Billot-Klein D, Gutmann L, Sablè S, Guittet E, van Heijenoort J. (1994):** Modification of peptidoglycan precursors is a common feature of the low-level vancomycin-resistant VANB-type *Enterococcus* D366 and of the naturally glycopeptide-resistant species *Lactobacillus casei*, *Pediococcus pentosaceus*, *Leuconostoc mesenteroides*, and *Enterococcus gallinarum*. *J Bacteriol.* 176:2398-405.
- Black, J.G. (1996):** Microbiolog. Principles and Applications. Third Edition. Prentice Hall. Upper Saddle River. New Jersey. PP. 436-449.
- Blazquez, J., M.-I. Morosini, M.-C. Negri, and F. Baquero. (2000):** Selection of naturally occurring extended-spectrum TEM β -lactamase variants by fluctuating β -lactam pressure. *Antimicrob Agents Chemother.* 44:2182-2184.
- Bonnet, R., C. D. Champs, D. Sirot, C. Chanal, R. Labia, and J. Sirot. (1999):** Diversity of TEM mutants in *Proteus mirabilis*. *Antimicrob Agents Chemother.* 43:2671-2677.
- Bonnet, R., J. L. M. Sampaio, R. Labia, C. D. Champs, D. Sirot, C. Chanal, and J. Sirot. (2000):** A novel CTX-M β -lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil. *Antimicrob Agents Chemother.* 44:1936-1942.
- Bou, G., A. Oliver, and J. Martinez-Beltrán. (2000):** OXA-24, a novel class D β -lactamase with carbapenemase activity in an *Acinetobacter baumannii* clinical strain. *Antimicrob Agents Chemother.* 44:1556-1561.

- Boyce JM, Opal SM, Chow JW, et al., (1994):** Outbreak of multidrug-resistant *Enterococcus faecium* with transferable *vanB* class vancomycin resistance. J Clin Microbiol. 32:1148-1153
- Boyle JF, Soumakis SA, Rendo A, et al., (1993):** Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin resistant enterococci. J Clin Microbiol. 31:1280-1285.
- Bradford P. A. (2001):** Extended-spectrum β -lactamase in the 21st century: characterization, epidemiology and detection of this important resistance threat. Clin Microbial Rev, 14:933-51.
- Bradford, P. A. (1999):** Automated thermal cycling is superior to traditional methods for nucleotide sequencing of *bla_{SHV}* genes. Antimicrob Agents Chemother.43:2960-2963.
- Bradford, P. A., C. Urban, N. Mariano, S. J. J. Rahal, and K. Bush, (1997):** Imipenem resistance in *Klebsiella pneumoniae* is associated with the combination ACT-1, a plasmid-mediated AmpC β -lactamase and the loss of an outer membrane protein. Antimicrob Agents Chemother. 41:563-569.
- Bradford, P. A., Y. Yang, D. Sahm, I. Grope, D. Gardovska, and G. Storch. (1998):** CTX-M-5, a novel cefotaxime-hydrolyzing β -lactamase from an outbreak of *Salmonella typhimurium* in Latvia. Antimicrob Agents Chemother. 42:1980-1994.
- Branger, C., A. L. Lesimple, B. Bruneu, P. Berry, and N. Lambert-Zechovsky. (1998):** Long-term investigation of the clonal dissemination of *Klebsiella pneumoniae* isolates producing extended-spectrum β -lactamase in a university hospital. J. Med. Microbiol. 47:210-219.

- Bujdakova H, Hanzen J, Jankovicova S, Klimackova J, Moravcikova M, Milosovic P, Michalkova-Papajova D, Kallova J, Jakab A, Kettner M. (2001):** Occurrence and transferability of beta-lactam resistance in Enterobacteriaceae isolated in Children's University Hospital in Bratislava. *Folia Microbiol (Praha)*.; 46:339–44.
- Bush K., Jacoby G.A., Medeiros AA. (1995):** A functional classification scheme for β -lactamases and its correlation with molecular structure. *Antimicrob Agents Chemother*. 39:1211-1233.
- Bush, K., and Singer S. B. (1989):** Biochemical characteristics of extended broad spectrum β -lactamases. *Infection* 17:429-433.
- Carter, M. W., K. J. Oakton, M. Warner, and D. M. Livermore. (2000):** Detection of extended-spectrum β -lactamases in *klebsiellae* with the Oxoid combination disk method. *J. Clin. Microbiol*. 38:4228-4232.
- Casellas, J. M., and M. Goldberg. (1989):** Incidence of strains producing extended-spectrum β -lactamases in Argentina. *Infection* 17:434-436.
- Chanawong, A., F. H. M'Zali. J. Heritage, A. Lulitanond, and P. M. Hawkey. (2000):** Characterization of extended- spectrum β -lactamase of the SHV family using a combination of PCR-single strand conformational polymorphism (PCR-SSCP) and PCR-restriction fragment length polymorphism (PCR-RFLP). *FEMS Microbiol.Lett*. 184:85-89.
- Clewell DB. (1990):** Movable genetic elements and antibiotic resistance in enterococci. *Eur J Clin Microbiol Infect Dis*. 9:90-102.
- Clinical laboratory standards institute (2005):** Performance Standards for Antimicrobial Susceptibility Testing.

- Coffey TJ, Dowson CG, Daniels M, Spartt BG. (1993):** Horizontal spread of an altered penicillin-binding protein 2B gene between *Streptococcus pneumoniae* and *Streptococcus oralis*. FE1MS Microbiol Lett . 110:335-40.
- Cormican, M. G., A. Marshall, and R. N. Jones. (1996):** Detection of extended-spectrum β -lactamase (ESBL)-producing strains by the E test ESBL screen. J. Clin. Microbiol. 34:1880-1884.
- Coron F, Pestel, M, Kitzis M.D, Lemeland JF, Humbert G, Gutmann L. (1995):** Comparison of different β -lactam glycopeptide gentamicin combination for an experimental endocarditis caused by a highly β -lactam resistant and highly glycopeptide-resistant isolate of *Enterococcus faecium*. J Infect Dis; 171-106-12.
- Cotton, M.F., E. Wasserman, C H. Pieper, D. C. Theron, D. van Tubbergth G. Campbell, F. C. Fang, and J. Barnes. (2000):** Invasive disease due to extended-spectrum β -lactamase-producing *Klebsiella pneumoniae* in a neonatal unit: the possible role of cockroaches. J. Hosp. Infect. 44:13-17.
- Coudron, P. E., E. S. Moland, and C. C. Sanders. (1997):** Occurrence and detection of extended-spectrum β -lactamases in members of the family *Enterobacteriaceae* at a Veterans Medical Center: seek and you may find. J.Clin. Microbiol. Agents Chemother. 35:2593-2597.
- Cullman, W.(1990):** Interaction of beta-lactamase inhibitors with various beta-lactamases. Chemotherapy 36:200-208
- Danel, F., L. M. C. Hall, B. Duke, D. Gur, and D. M. Livermore. (1999):** OXA-17, a further extended-spectrum variant of OXA-10 β -lactamase, isolated from *pseudomonas aeruginosa*. Antimicrob Agents Chemother. 43:1362-1366.

- Daniel J. Diekema, Angela B. Brueggemann, Gary. V. Doern. (2000):**
Antimicrobial-Drug use and changes in resistance *Streptococcus pneumoniae*. Emerging Infectious Diseases Vol.6, No.5 Sep.
- Datta, N., and P. Kontomichalon. (1965):** Pennicillinase synthesis controlled by infectious R Factors in Enterobacteriaceae. Nature 208:239-244.
- Deville J,G; Adler S, AzimiI PH,. (2003):** Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J . Sep; 22(9 Suppl): S 158-163.
- Doern GV, Brueggemann A, Holley HP Jr, & Rauch AM. (1996):**
Antimicrobial resistance of *Streptococcus pneumoniae* recovered from outpatients in the United States during the winter months of 1994 to 1995: result of a 30- center national surveillance study. Antimicrob. Agents Chemother 40:1208-13.
- Doucet-Populaire, F., J. C. Ghnassia, R. Bonnet, and J. Sirot. (2000):**
First isolation of a CTX-M-3-producing *Enterobacter cloacae* in France. Antimicrob Agents Chemother. 44:3239-3240.
- Ehrhardt, A. F., and. Sanders C. C. (1993):** Beta-lactamase resistance among Enterobacter species J. Sntimicrob. Agents Chemother 32 (Suppl.B):1-11.
- Emery, C. L., and L. A. Weymouth. (1997):** Detection and clinical significance of extended-spectrum β -lactamase in a tertiary-care medical center. J. Clin. Microbiol 53:2061-2067.
- Ena J, Dick RW, Jones RN,Wenzel RP. (1993):** The epidemiology of intravenous vancomycin usage in a university hospital. JAMA. 269:598-602.

- Fanti B, Pangon B, Potel G, et al. (1990):** Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by *Escherichia coli* producing SHV-2 like β -lactamase. *Antimicrob Agents Chemother.* 34:581-6.
- Figueiredo AM, Conner JD, Severin A, Vaz Pato MV, Tomasz A. (1992):** A pneumococcal clinical isolate with high-level resistance to cefotaxime and ceftriaxone. *Antimicrob Agents Chemother.* 36:886-9.
- Finland M. (1942):** Recent advances in the epidemiology of pneumococcal infections. *Medicine (Baltimore).* 21:307-344.
- Fish D.N., Piscitelli S.C., Danziger L.H. (1995):** Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics. *Pharmacotherapy.* 15:279–291.
- Forbes, Sahmand and Weissfeid. (1998):** Bailey & Scott's diagnostic microbiology, 10th ed. Mosby, Inc., St. Louis, Mo.
- Fraimow HS & Abrutyn E. (1995):** Pathogens resistant to antimicrobial agents- epidemiology, molecular mechanisms, and clinical management. In: *Antibacterial Therapy: in Vitro Testing, Pharmacodynamics, Pharmacology, New Agents. Infectious Disease Clinics of North America.* 9:497-530.
- Freidland IR, Paris M, Ehrett S, Hickey S, Olsen K, McCracken GH Jr. (1993):** Evaluation of antimicrobial regimens for treatment of experimental penicillin and cephalosporin-resistant pneumococcal meningitis. *Antimicrob Agents Chemother.* 37:1630-1636.
- Gaillot O, Clement C, Simonet M, Philippon A. (1997):** Novel transferable β -lactam resistance with cephalosporinase characteristics in *Salmonella enteritidis*. *J Antimicrob Chemother.* 39:85–87.

- Gaillot, O., C. Maruèjols. É. Abachin, F. Lecuru, G. Arlet, M. Simonet, and P. Berche. (1998):** Nosocomial outbreak of *Klebsiella pneumoniae* producing SHV-5 extended-spectrum β -lactamase, originating from a contaminated ultrasonography coupling gel. J. Clin. Microbiol. 36:1357-1360.
- Garner JS.: (1996):** The Hospital Infection Control Practices Advisory Committee . Infect Control Hosp Epidemiol Jan ;17(1): 53-80.
- Gaynes R, Edwards J, National (1996):** Nosocomial Infection Surveillance (NNIS) System. Nosocomial vancomycin Resistant Enterococci (VRE) in the United States, 1989-1995: the first 1000 isolates. Infect Control Hosp Epidemiol. 17:Suppl :P18.
- Gazouli, M., N. J. Legakis, and L. S. Tzouvelelakis. (1998):** Effect of substitution of Asn for Arg-276 in the cefotaxime-hydrolysing class A β -lactamase CTX-M-4. FEMS Microbiol. Lett. 169:289-293.
- Gazouli, M., S. V. Sidorenko, E. Tzelepi, N. S. Kozlova, D. P. Gladin, and L. S. Tzouvelekis. (1998):** A plasmid-mediated β -lactamase conferring resistance to cefotaxime in *Salmonella typhimurium* clone found in St. Petersburg, Russia. J. Antimicrob. Chemother. 41:119-121.
- Gençer S, Ak Ö, Benzonana N, Batirel A, Özer S. (2002):** Susceptibility patterns and cross resistance of antibiotics against *Pseudomonas aeruginosa* in a teaching hospital of Turkey. Ann Clin Microbial Antimicrob. 1:2.
- Ghuysen, J. M. (1991):** Serine β -lactamase and Penicillin-binding Proteins. Annu. Rev. Microbiol, 45:37-67.

- Gniadkowski, M., A. Palucha, P. Grzesioski, and W. Hrynewiez. (1998):** Outbreak of ceftazidime-resistant *Klebsiella Pneumoniae* in a pediatric hospital in Warsaw, Poland: clonal spread of the TEM-47 extended-spectrum β -lactamase (ESBL)-producing strain and transfer of a plasmid carrying the SHV-5-like ESBL-encoding gene. *Antimicrob Agents Chemother.* 42:3079-3085
- Goldstein FW (2002):** Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. *Clin Microbiol Infect.* 8:823–825
- Grayson ML, Eliopoulos GM, Wennersten CB, et al., (1991):** Increasing resistance to β -lactam antibiotics among clinical isolates of *Enterococcus faecium*: a 22 year review at one institution. *Antimicrob Agents Chemother.* 35:2180-2184.
- Hall, L. M. C., D. M. Livermore, D, Gur, M. Akova, and H, E. Akaline. (1993):** OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) β -lactamase from *Pseudomonas aeruginosa*. *Antimicrob Agents. Chemother.* 37:1637-1644.
- Handwerger S, Raucher B, Altarac D, et al., (1993):** Nosocomial outbreak due to *Enterococcus faecium* highly resistant to vancomycin, penicillin, and gentamicin. *Clin Infect Dis.* 16:750-755.
- Hawkey PM. (1998):** The origins and molecular basis of antibiotic resistance. *British Medical Journal.* 317:657-660.
- Ho, P, L., D. N. C. Tsang, T. L. Que, M. Ho. And K. Y. Yuen. (2000):** Comparison of screening methods for detection of extended-spectrum β -lactamases and their prevalence among *Escherichia coli* and *Klebsiella* species in Hong Kong. *APMIS* 108:237-240.

- Ho, P, L., K. H. Chow, k. Y. Yuen, W. S. Ng, and P. Y. Chau. (1998):** Comparison of a novel, inhibitor-potentiated disc-diffusion test with other method for the detection of extended-spectrum β -lactamases in *Escherichia coli* and *Klebsiella pneumoniae*, J. Antimicrob Agents Chemother. 42:49-54.
- Howard, S. Gold, and Robert C. Moellering. (1996):** Antimicrobial-Drug Resistance-Review article. NEJM Volume 335:1445-1445.
- Huber, T.W and Thomas J.S, (1994):** Detection of resistance due to inducible beta-lactamase in *Enterobacter aerogenes* and *Enterobacter cloacae*. J Clin Microbiol. 1994 October; 32(10): 2481-2486
- Huletsky, A., J. Knox, and R. C. Levesque. (1993):** Role of Ser-238 and Lys-240 in the hydrolysis of 3rd-generation cephalosporins by SHV- type β -lactamases probed by site-directed mutagenesis and 3-dimensional modeling. J. Biol. Chem. 268:3690-3697.
- Humeniuk, G. Arlet, R. Labia, P. Grimont, and A. Phillion, (2000):** Abstract. Rénion Interdis. Chimiothet. Anti-infect.
- Ibuka, A., A. Taguchi, M. Ishiguro, S. Fushinobu, Y. Ishii, S. Kamitori, K. Okuyama, K. Yamaguchi, M. Konno, and H. Matsuzawa. (1999):** Crystal structure of the E166A mutant of extended-spectrum β -lactamase Toho-1 at 1.8 Å resolution. J. Mol. Biol. 285:2079.
- Ingerman MJ, Santoro J. (1989):** Vancomycin: a new old agent. Infect Dis Clin North Am. 3:641:651.
- Jacobs MR, Koornhof HJ & Robins-Browne RM,. (1978):** Emergence of multiply resistant pneumococci. N Engl J Med. 299:735-740.
- Jacoby, G, A., and A. A. Medeiros. (1991):** More extended-spectrum β -lactamases. Antimicrob Agents Chemother . 35:1697-1704.

- Jacoby, G, A., and P. Han. (1996):** Detection of extended spectrum β -lactamase in clinical isolates of *Klebsiella pneumoniae* and *Escherichia coli*. J. Clin. Microbiol. 34:908-911.
- Jacoby, G. A., and L. Sutton. (1991):** Properties of plasmids responsible for production of extended-spectrum β -lactamases. Antimicrob Agents. Chemother. 35:164-169.
- Jacoby, G. A., and P. Han. (1996):** Detection of extended spectrum β -lactamase I clinical isolates of *Klebsiella pneumoniae* and *Escherichia coli*. J. Clin. Microbiol. 34:908-911.
- Jarlier, V., M. Nicolas, G. Fournier, and A. Philippon . (1988):** Extended-spectrum β -lactamases conferring transferable resistance to newer β -lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev. Infect. Dis. 10; 867-878.
- Jenkins SG. (1996):** Mechanisms of bacterial antibiotic resistance. New Horizons. 4:321-332.
- Jing-Jou Yan, Wen-Chien Ko, Hsiu-Mei Wu, Shu-Huei Tsai, Chin-Luan Chuang, and Jiunn-Jong Wu, (2004):** Complexity of *Klebsiella pneumoniae* Isolates Resistant to Both Cephamycins and Extended-Spectrum Cephalosporins at a Teaching Hospital in Taiwan J Clin Microbiol. 2004 November; 42(11): 5337–5340.
- John, J. F. J., and L. B. Rice. (2000):** The microbial genetics of antibiotic cycling. Infect. Control Hosp. Epidemiol. 21:S22-S31.
- Jones RN, Kebrberg EN, Erwin ME & Anderson SC. (1994):** Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistance: real or perceived? Diagn Microbiol Infect Dis. 19:203-215.

- Jorgensen JH, Ferraro M J, McElmeel ML, Spargo J, Swenson JM, Tenover FC. (1994):** Detection of penicillin and extended-spectrum cephalosporin resistance among *Streptococcus pneumoniae* clinical isolates by use of the E test. J Clin Microbiol 32:159-163.
- Kanra GY, Ozen H, Secmeer G, Ceyhan M, Ecevit Z, Belgin E. (1995):** Beneficial effects of dexamethasone in children with pneumococcal meningitis. Pediatr Infect Dis J. 14:490-494.
- Katsanis, G.P., J. Spargo, M. J. Ferraro, L. Sutton, and G.A. Jacoby. (1994):** Detection of *Klebsiella pneumoniae* and *Escherichia coli* strains producing extended- spectrum β -lactamases. J. Clin. Microbiol. 32:691-696.
- Kim, J., and H.-J. Lee. (2000):** Rapid discrimination detection of gene coding for SHV β -lactamases by ligase chain reaction. Antimicrob Agents Chemother. 44:1860-1864.
- Kim, J., Y. Kwon, H. Pai, J.-W. Kim, and D.-T. Cho. (1998):** Survey of *Klebsiella pneumoniae* strains producing extended-spectrum β -lactamases: prevalence of SHV-12 and SHV-2a in Korea. J. Clin. Microbiol. 36:1446-1449.
- Klare I, Heier H, Claus H, Reissbrodt R, Witte W, (1995):** VanA-mediated high-level glycopeptide resistance in *Enterococcus faecium* from animal husbandry. FEMS Microbiol Lett. 125:165-171.
- Kliebe, C., B. A. Nies, J. F. Meyer, R. M. Tolxdorff-Neutzling, and B, Wiedemann. (1985):** Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother. 28:302-307.

- Koneman, E.W., et al. (1997):** Color Atlas and Textbook of Diagnostic Microbiology, 5th ed., J.B. Lippincott, Philadelphia, PA.
- Konthe H, Shah P, Kremèry V, Antal M, Mitsuhashi S. (1993):** Transferable resistance to cefotaxime, ceftiofur, cefamandole and cefuroxime in clinical isolates of *klebsiella pneumoniae* and *Serratia marcescens*. Infection. 11:315-317.
- Krogstad DJ & Pargwette AR. (1980):** Defective killing of enterococci: a common property of antimicrobial agents acting on the cell wall. Antimicrobe Agents Chemother. 17:965-968.
- Kuga A, Okamoto R, Inoue M. (2000):** ampr gene mutations that greatly increase class C β -lactamase activity in *Enterobacter cloacae*. Antimicrob Agents Chemother. 44:561–567.
- Labile G, Spratt BG, Hakenbeck R. (1991):** Interspecies recombinational events during the evolution of altered PBP 2x genes in penicillin-resistant clinical isolates of *Streptococcus pneumoniae*. Mol Microbiol. 5:1993-2002.
- Levy SB. (1998):** Antimicrobial resistance: bacteria on the defence. *British Medical Journal*. 317:612-613.
- Livermore DM, Brown DF. (2001):** Detection of β -lactamase-mediated resistance. J Antimicrob Chemother. 48:59–64.
- Livermore DM. beta-Lactamases (1997):** Quantity and resistance. Clin Microbiol Infect.;3:S10–S19.
- Livermore, D. M. (1995):** β -lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8:557-584.
- Livermore, D. M. and Yuan. (1996):** Antibiotic resistance and production of extended-spectrum β -lactamase among *Klebsiella* spp. From intensive care units in Europe. J. Antimicrob. Chemother. 38:409-424.

- Lucet, J.-C., D. Decrè, A. Fichelle, M.-L. Joly-Guillou, M. Pernet, C. Deblangy, M. –J. Kosmann, and B. Règnier. (1999):** Control of a prolonged outbreak of extended-spectrum β -lactamase-producing *Enterobacteriaceae* in a university hospital. Clin. Infect. Dis. 20:1411-1418.
- Ma, L., Y. Ishii, M. Ishiguro, H. Matsuzawa, and K. Yamaguchi. (1998):** Cloning and sequencing of the gene encoding Toho-2, a class A β -lactamases preferentially inhibited by tazobactam. Antimicrob Agents Chemother. 42:1181-1186.
- Mabilat, C., and P. Courvalin. (1990):** Development of "oligotyping" for characterization and molecular epidemiology of TEM β -lactamases in members of the family *Enterobacteriaceae*. Antimicrob Agents Chemother. 34:2210-2216.
- Marchandin, H., C. Carriere, D. Sirot, H. Jean-Pierre, and H. Darabs. (1999):** TEM-24 produce by four different species of *Enterobacteriaceae*, including *Providencia rettgeri*, in a single patient. Antimicrob Agents Chemother. 43:2069-2073.
- Martínez-Martínez, L., S. Hernández-Allés, S. Albertí, J. Tomás, V. Benedi, and G. Jacoby. (1996):** In Vivo selection of porin-deficient mutants of *Klebsiella pneumoniae* with increased resistance to cefoxitin and expanded-spectrum cephalosporins. Antimicrob Agents Chemother. 40:342-348.
- Matsumoto, Y., and M. Inoue. (1999):** Characterization of SFO-1, a plasmid-mediated inducible class A β -lactamases from *Enterobacter cloacae*. Antimicrob Agents Chemother. 43:307-313.

- McGeer A., Low D.E, Conly J., (1996):** The rapid emergence of a new strain of MRSA And infection Ontario: Laboratory and infection control implications. Laboratory Proficiency Testing Program Newsletter No.190, October 29, 1-4.
- McManus MC. (1997):** Mechanisms of bacterial resistance to antimicrobial agents. American Journal Health-Systems Pharmacology. 54:1420-1433.
- Medeiros, A. A. (1984):** β -lactamases.Br. Med. Bull.40:18-27.
- Medeiros, A. A., and J. Crellin. (1997):** Comparative susceptibility of clinical isolates producing extended-spectrum β -lactamase to ceftibuten: effect of a large inoculum. *Pediatr. Infect. Dis. J.* 16:S49-S55.
- Medeiros, A., K. H. Mayer, and S. M. Opal. (1988):** Plasmid-mediated β -lactamases. *Antimicrob. Newsl*.5:61-65.
- Meyer K.S.,C.Urban, J.A Eagan, B.J. Berger, , J.J Rahal. (1993):** Nosocomial outbreak of *Klebsiella infection* resistant to late-generation cephalosprins. *Ann Intern Med.* 119-353-358.
- Moellering RC Jr. (1981):** Antimicrobial susceptibility of enterococci: in vitro studies of action of antibiotics alone and in combination. In: Bisno Al., ed. *Treatment of infective endocarditis*. New York: Grune & Stratton. :81-96.
- Moellering RC Jr. (1992):** Emergence of *Enterococcus* as a significant pathogen. *Clin Infect Dis.* 14:117-6.
- Mugnier, P., P. Dubrous, I. Casin, G. Arlet, and E. Collatz. (1996):** A TEM-derived extended-spectrum β -lactamase in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 40:2488-2493.

- Munford RS, Murphy TV. (1994):** Antimicrobial resistance in *Streptococcus pneumoniae*: can immunization prevent its spread? J Invest Med. 42:613-621.
- Munzo R, Musser JM, Crain M., (1992):** Geographic distribution of penicillin-resistant clones of *Sreptococcus pneumoniae*: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis. Clin Infect Dis. 15:112-118.
- Murray BE. (1997):** Antibiotic resistance. Adv Intern Med. 1997;42:339–67.
- Murray, P.R., et al (1999):** . Manual of Clinical Microbiology, 6th ed. American Society for Microbiology, Washington DC.
- M'Zali, F.-H., D. M. Gascoyne-Binzi, J. Heritage, and P. M. Hawkey. (1996):** Detection of mutations conferring extended-spectrum activity on SHV β -lactamases using polymerase chain reaction single strand conformational polymorphism (PCR-SSCP). J. Antimicrob. Chemother. 37:797-802.
- M'Zali, F.-H., J. Heritage, D. M. Gascoyne-Binzi, A.M. Snelling, and P. M. Hawkey. (1998):** PCR single strand conformational polymorphism can be used to detect the gene encoding SHV-7extended-spectrum β -lactamase and to identify different SHV genes within the same strain. J. Antimicrob. Chemother. 41:123-125.
- Naas, T., L. Poirel, A. Karim, and P. Nordmann. (1999):** Molecular characterization of In50, a class1 integron encoding the gene for the extended-spectrum β -lactamase VEB-1 in *pseudomonas aeruginosa*. FEMS Microbiol. Lett. 176:411-419.

- Nadal, D., and Graevenitz A. von. (1993):** Routine detection of inducible beta-lactamase in gram-negative bacilli by means of disk susceptibility testing. *J. Microbiol. Methods* 17:283-291.
- Nass, T., L. Philippon, L. Poirel, E. Ronco, and P. Nordman. (1999):** An SHV-derived extended-spectrum β -lactamase in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 43:1281-1284..
- National Committee for Clinical Laboratory Standards.(NCCL) (1993):** Performance standards for antimicrobial disk susceptibility tests,
- National Committee for Clinical laboratory standards. (2000):** Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Approved standard M7-A5 and informational supplement M100-S10. National Committee for Clinical laboratory standards, **Wayne, Pa.**
- National Nosocomial Infection Surveillance (NNIS). (2003):** System Report, data summary from January 1992 through June.2003, issued August 2003 [Electronic version] *American Journal of Infection Control*, 31 No. 8,481-498.
- Naumovski L, Quinn JP, Miyashiro D. (1992):** Outbreak of ceftazidime resistance due to a novel extended-spectrum β -lactamase in isolates from cancer patients. *Antimicrob Agents Chemother.* 36:1991-1996.
- Neu H, & Gootz TD (1996):** Antimicrobial Chemotherapy. Baron S, Schuenke S, Editors. *Medical Microbiology*. 4th ed. Galveston, TX: University of Texas Medical Branch at Galveston.
- Noble WC, Virani Z, Cree RGA. (1992):** Co-transfer of vancomycin and other resistance genes from *Enterococcus faecalis* NCTC 12201 to *staphylococcus aureus*. *FEMS Microbiol Lett.* 93:195-198.

- Nordman, P., E. Ronco, T. Naas C. Duport, Y. Michel-Briand, and R. Labia. (1993):** Characterization of a novel extended-spectrum β -lactamase from *Pseudomonas aeruginosa*. Antimicrob Agents Chemother. 37:962-969.
- Nordmann, P. (1998):** Trends in β -lactam resistance among Enterobacteriaceae. Clin. Infect. Dis. 27-S100-S106.
- Nordmann, P., L. Poirel, M. Kubina, A. Casetta, and Nass. (2000):** Biochemical-genetic characterization and distribution of OXA-22, a chromosomal and inducible class D β -lactamase from *Ralstonia (Pseudomonas) pickellii*. Antimicrob Agents Chemother. 44.2201-2204.
- Nüesch-Inderbilen, M. T., and F. H. K. H. Hächler. (1996):** Detection of gene coding for extended-spectrum SHV β -lactamases in clinical isolates by a molecular genetic method, and comparison with the E test. Eur. J. Clin. Microbiol. Infect. Dis. 15:398-402.
- Pai, H., S. Lyu, J. H. Lee, J. Kim, Y. Kown, J.-W Kim, and K. W. Choe (1999):** Survey of extended-spectrum β -lactamase in clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae*: prevalence of TEM-52 in Korea. J. Clin. Microbiol. 37:1758-1763.
- Pangon, B., C. Bizet, A. & Burè. (1989):** In vivo selection of cephamycin-resistant, porin-deficient mutant of *Klebsiella pneumoniae* producing a TEM-3 β -lactamase. J Infect Dis. 159:1005-1006.

- Paris MM, Hickey SM, Usher MI, Shelton S, Olsen KD, McCracken GH Jr. (1994):** Effect of dexamethasone on therapy of experimental penicillin and cephalosporins-resistant pneumococcal meningitis. *Antimicrob Agents Chemother.* 38:1320-1324.
- Paris MM, Ramilo O, McCracken GH Jr. (1995):** Management of meningitis caused by penicillin-resistant *Streptococcus pneumoniae* *Antimicrob Agents Chemother.* 39:171-175
- Paterson, D. L., and V. L. Yu. (1999):** Extended-spectrum β -lactamase: a call for improved detection and control. *Clin. Infect. Dis.* 29:1419-1422.
- Paterson, D. L., L. Mulazimoglu, J. M. Casellas, W. C. Ko, H. Goossens, A. Von Gottberg, S. Mohapatra, G. M. Trenholme, K. P. Klugman, J. G. McCormack, and V. L. Yu. (2000):** Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β -lactamases production in *Klebsiella pneumoniae* isolates causing bacteremia. *Clin. Infect. Dis.* 30:473-478.
- Patterson, J. E., T. Hardin, C. A. Kelly, R. C. Garcia, and J. H. Jorgensen. (2000):** Association of antibiotic utilization measure and control of multiple-drug resistance in *Klebsiella pneumoniae*. *Infect. Control Hosp. Epidemiol.* 21:445-458.
- Payne DJ, Cramp R, Winstanley DJ, & Knowlezs DJ. (1994):** Comparative activities of clavulanic acid, Sulbactam, and tazobactam against clinically important β -lactamases. *Antimicrob Agents Chemother.* 38:767-772.

- Peña, C., M. Pujol, A. Ricart, C. Ardanuy, J. Ayats, J.A.J. Liñares, F. Garrigosa, J. Ariza, and F. Gudiol. (1997):** Risk factors for faecal carriage of *Klebsiella pneumoniae* producing extended-spectrum β -lactamases in the intensive care unit. J. Hosp. Infect. 35:9-16.
- Peña, C., M. Pujol, C. Ardanuy, A. Ricart, R. Pallares, J. Liñares, and F. Gudiol. (1998):** Epidemiology and successful control of a large outbreak due to *Klebsiella pneumoniae* producing extended-spectrum β -lactamases Antimicrob Agents Chemother.42:53-58
- Performance standards for antimicrobial disk. (1993):** Susceptibility tests: approved standard. 5th ed. Vol. 13. No. 24. Villanova, Pa: National committee for Clinical Laboratory Standards 1993. (NCCLS document no. M2. A5.)
- Performance Standards for Antimicrobial Susceptibility Testing. (1995):** Sixth informational supplement M100-S6. Vol. 15. No. 14. Villananova, Pa: Nation-al Committee for clinical laboratory standards.
- Pettis, G.S., and S. Prakash. (1999):** Complementation of Conjugation Functions of Streptomycin Llividans Plasmid PIJ 101 by the related streptomycetes plasmid.Bacterial 181-4680-4685.
- Pfaller MA & RN. (2002):** Antimicrobial susceptibility of inducible AmpC β -lactamase-producing Enterobacteriaceae from the Meropenem Program Susceptibility Test Information Collection (MYSTIC) program, Europe 1994-2000. Int J Antimicrob Agents, 19;383-351.
- Philippon A, Labia R, & Jacoby G (1989):** Extended-spectrum β -lactamases. Antimicrob. Agents Chemother 33:1131-1136.

- Philippon, L., H., T. Naas, A.-T Bouthors, V. Barakett, and P. Nordmann. (1997):** OXA-18, a class D clavulanic acid-inhibited extended-spectrum β -lactamase from *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 41;2188-2195.
- Piroth, L. N., Aubè, J.-M. Doise, and Vincent-Martin. (1998):** Spread of extended-spectrum β -lactamase producing *Klebsiella pneumoniae*: are β -lactamase inhibitors of therapeutic value? *Clin. Infect. Dis.* 27:76-80.
- Poirel L, Guibert M, Girlich D, Naas T, Nordmann P. (1999):** Cloning, sequence analyses, expression, and distribution of ampC-ampR from *Morganella morganii* clinical isolates. *Antimicrob Agents Chemother.* 43:769–76.
- Poirel, L., I. L. Thomas, T. Naas, A. Karim, and P. Nordman, (2000):** Biochemical sequence analyses of GES-1, a novel class A extended-spectrum β -lactamase, and the class 1 integron IN52 from *Klebsiella Pneumoniae*. *Antimicrob Agents Chemother.* 44;622-632.
- Poirel, L., M. Guibert, D. Girlich, T. Naas, and P. Nordmann. (1999):** Cloning, sequence analysis, expression, and distribution of ampC-ampR from *Morganella morganii*. *Antimicrob Agents Chemother.* 43:769-776.
- Poirel, L., T. Naas, M. Guibert, E. B. Chaibi, R. Labia, and P. Nordmann. (1999):** Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum β -lactamase encoded by an *Escherichia coli* integron gene *Antimicrob Agents Chemother.* 43;573-581.
- Ponce de León RS, Molinar Ramo F, Dominguez Cherit G. Rangel Frausto S, Vázquez Ramos VG. (2000):** Prevalence of infections

in intensive care units in Mexico: A multicenter study. *City Care Med*; 28:1316-1321.

Power, David A. (ed.). (1988): Manual of BBL products and laboratory procedures, Sixth Edition, Becton Dickinson Microbiology System, Cockeysville, MD.

Quellette, M., G. C. Paul, A. M. Philippon, and P. H. Roy. (1988): Oligonucleotide probes (TEM-1, OXA-1) versus isoelectric focusing in β -lactamases characterization of 114 resistant strains. *Antimicrob Agents Chemother.* 32:397-399.

Quintiliani R Jr, Evers S, Courvalin P. (1993): The *van B* gene confers various levels of self-transferable resistance to vancomycin in enterococci. *J Infect Dis.* 167:1220-1223.

Rasheed, J. K., C. Jay, B. Metchock, F. Berkowitz, L. Weigel, J. Crellin, C. Steward, B. Hill, A. A. Medeiros, and F. C. Tenover. (1997): Evolution of extended-spectrum β -lactam resistance (SHV-8) in a strain of *Escherichia coli* during multiple episodes of bacteremia. *Antimicrob Agents Chemother.* 41:647-653.

Reves RR, Jones JA. (1990): Antibiotic use and resistance: patterns in day care centers. *Semin Pediatr Infect Dis.* 1:212-221.

Rice LB, Carias LL, Shales DM. (1994): In vivo efficacies of β -lactamase inhibitor combinations against a TEM-26- producing strain of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 38:2663-2664.

Rice LB, Willey SH, & Papanicolaou GA, et al., (1990): Outbreak of ceftazidime resistance caused by extended-spectrum β -lactamases at a Massachusetts chronic-care facility. *Antimicrob Agents Chemother.* 34:2193-2199.

- Rice, L. B. (1999):** Successful intervention for gram-negative resistance to extended-spectrum β -lactam antibiotics. *Pharmacotherapy* 19:120S-128S.
- Rice, L. B., C. Eckstein, J. DeVente, and D. M. Shlaes. (1996):** Ceftazidime-resistant *Klebsiella pneumoniae* isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. *Clin. Infect. Dis.* 23:118-124.
- Rice, L. B., J. D. C. Yao, K. Klimm, G. M. Eliopoulous, and R. C. Moellering. (1991):** Efficacy of different β -lactamase against an extended-spectrum β -lactamase producing *Klebsiella pneumoniae* strain in the rat intra-abdominal abscess model. *Antimicrob Agents Chemother.* 35:1243-1244.
- Rice, L. B., L. L. Carias, A. M. Hujer, M. Bonfede, R. Hutton, C. Huyen, and R. A. Bonomo. (2000):** High-level expression of chromosomally encoded SHV-1 β -lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolates of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 44:362-367.
- Richards MJ. Edwards JR, Cukver DH, Gaynes RP.(1999):** National Nosocomial Surveillance System. Nosocomial infections in medical intensive care units in the United States. *Crit Care Med* 27:887-892.
- Richmond, M. H., and R. B. Sykes (1973):** The β -lactamase of gram-negative bacteria and their possible physiological role. *Adv. Microb. Physiol.* 9:31-88.
- Rosenau, A., B. Cattier, N. Gousset, P. Harriau, A. Philippon, and R. Quentin. (2000):** *Capnocytophaga ochracea*: characterization of a plasmid-encoded extended-spectrum TEM-17 β -lactamase in

the phylum *Flavobacter-Bacteroides*. Antimicrob Agents Chemother.44;760-762.

Rosenthal V.D.Guzman S, Pezzotto S.M., Ccrnich C.J. (2003): Effect of an infection control program using education and performance feedback on rates of intravascular device-associated blood stream infections in intensive care units in Argentina. Am J Infect Control; 31(7):405-409.

Rosenthal V.D.Guzman S, Safdar N. (2004): Effect of education and performance feedback on rates of catheter-associated urinary tract infection in intensive care units in Argentina. Infect Control Hosp. Epidemiol; 25(1):47-50.

Rossolini, G. M., N. Franceschini, L. Lauretti, B. Caravelli, M. L. Riccio, M. Galleni, J.-M. Frère, and G. Amicosante. (1999): Cloning of a *Chryseobacterium* (*Flavobacterium*) *menigiosepticum* chromosomal gene (*bla*_{ACME}) encoding an extended-spectrum class A β -lactamase related to the *Bacteroides* cephalosporinases and the VEB-1 and PER β -lactamases. Antimicrob Agents Chemother.43; 2193-2199.

Sabaté, M., R. Tarragó, F. Navarro, E. Miró, C. Vergés, J. Barbé, and G. Prats. (2000): Cloning and sequence of the gene encoding a novel cefotaxime-hydrolyzing β -lactamase (CTX-M-9) from *Escherichia coli* in Spain. Antimicrob Agents Chemother; 44:1970-1973.

- Sader HS, Pfaller MA, Jones RN (1994):** Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. J I. Study of intra- and interlaboratory dissemination of extended-spectrum β -lactamase-producing *Enterobacteriaceae*. Digan Microbiol Infect Dis. 20:203-208.
- Sader HS, Pfaller MA, Tenover FC, Hollis RJ, Jones RN. (1994):** Evaluation and characterization of multiresistant *Enterococcus faecium* from 12 U.S medical centers. J Clin Microbiol. 32:2840-2842.
- Sanders WE Jr, & Sanders CC. (1988):** Inducible β -lactamases; clinical and epidemiologic implication for use of newer cephalosporins, Rev Infect Dis. 10:830-888.
- Sanders, C. C., A. L. Barry, J. A. Washington, C. Shubert, E. S. Moland, M. M. Traczewski, C. Knapp, and R. Mulder, (1996):** Detection of extended-spectrum- β -lactamase-producing members of the family *Enterobacteriaceae* with the Vitek ESBL test. J. Clin. Microbiol. 34:2997-3001.
- Sanders, C. C., and Sanders W. E., Jr. (1979):** Emergence of resistance to cefamandole: possible role of ceftioxin-inducible β -lactamases. Antimicrob. Agents Chemother. 15:792-797.
- Sanders, C. C., M. Peyret, E. S. Moland, C. Shubert, K. S. Thomson, J.-M. Bouffgras, and W, E. Sanders Jr. (2000):** Ability of the VITEK 2 Advanced Expert system to identify β -lactam phenotypes in isolates of *Enterobacteriaceae* and *Pseudomonas aeruginosa*. J. Clin. Microbiol. 38:570-574.

- Schaberg DR, Culver DH, Gaynes RP. (1991):** Major trends in the microbial etiology of nosocomial infection. Am J Med 91: Suppl 3B:3B-72S- 3B-75S.
- Shay DK, Maloney SA, Montecalvo M, et al. (1995):** Epidemiology and mortality risk of vancomycin- resistant enterococcal bloodstream infections. J Infect Dis. 172:993-1000.
- Shlaes DM, Etter L, Gutmann L. (1991):** Synergistic killing of vancomycin resistant enterococci of class A, B, and C by combination of vancomycin, penicillin, and gentamicin. Antimicrob Agents Chemother. 35:776-779.
- Siebert T.D., Thomson RB Jr, Tan JS, Gerson LW. (1993):** Emergence of antimicrobial resistance in gram-negative bacilli causing bacteremia during therapy. Am J clin pathol,100: 47-51.
- Silva, J., C. Aguilar, G. Ayala, M. A. Estrada, U. Garza-Ramos, R. Lara-Lemus, and L. Ledezma. (2000):** TLA-1: a new plasmid-mediated extended-spectrum β -lactamases form *Escherichia coli*. Antimicrob Agents Chemother 44:997-1003.
- Sirot D, De Champs C, Chanal C, (1993):** Translocation of antibiotic-resistance determination including an extended-spectrum β -lactamase between conjugative plasmid of *klebsiella pneumoniae* and *Escherichia coli*. Antimicrob Agents Chemother. 35:15765-81.
- Siu, L. K., J. Y. C. Lo., K. Y. Yuen, P. Y. Chau, M. H. Ng. And P. L. Ho. (2000):** β -lactamases in *Shigella flexneri* isolates from Hong Kong and Shanghai and a novel OXA-1-like β -lactamase, OXA-30. Antimicrob Agents Chemother. 44:2034-2038.

- Sougakoff W, Goussard S, Gèrbaud G, Couvalin P. (1998):** Plasmid-mediated resistance to third-generation cephalosporins caused by point mutations in TEM-type penicillinase genes, *Rev Infect Dis.* 10:879-884.
- Sougakoff, W., S. Goussard, and P. Courvalin. (1988):** The TEM-3 β -lactamases, which hydrolyzes broad-spectrum cephalosporins, is derived from the TEM-2 penicillinase by two amino acid substitutions. *FEMS Microbiol. Lett.* 56:343-348.
- Steel, K.J. *APPI, J. Bact.*, 25,445 (1962).** The oxidase test product.
- Steward, C. D., D. Wallace, S. K. Hubert, R. Lawton, S. K. Fridkin. R. P. Gaynes. J. E. M. Jr., and F. C. Tenover. (2000):** Ability of laboratories to detect emerging antimicrobial resistance in nosocomial Pathogens; a survey of Project ICARE laboratories. *Diagn. Microbiol. Infect. Dis.* 38:59-67.
- Stobberingh, E. E., J. Arends, J. A. A. Hoogkamp-Korstanje, W. H. F. Goessens, M. R. Visser, A. G. M. Buiting, Y. J. Debets-Ossenknopp, R. J. V. Ketel M. L. V. Ogtrop, L. J. M. Sabbe, G. P. Voorn. H. L. J. Winter and J. H. van Zeijl. (1999):** Occurrence of extended-spectrum β -lactamase in Dutch hospitals. *Infection* 27:348-5-354.
- Swenson JM, Clark NC, Ferraro MJ, et al., (1994):** Development of a standardized screening method for detection of vancomycin resistant enterococci. *J Clin Microbiol.* 32:1700-1704.
- Szabó, D., Z. Filetóth, J. Szentandrassy, M. Nèmedi, E. Tóth, C. Jeney, G. Kispál, and F. Rozgonyi. (1999):** Molecular epidemiology of a cluster of cases due to *Klebsiella pneumoniae* producing SHV-5 extended-spectrum β -lactamase in the premature intensive care unit of a Hungarian hospital. *J. Clin. Microbiol.* 37:4167-4169

- Tenover FC, Swenson JM, O'Hara CM, Stocker SA. (1995):** Ability of commercial and reference antimicrobial susceptibility testing methods to detect vancomycin resistance in enterococci. *J Clin Microbiol.* 33:1524-1527.
- Tenover, F. C., J. M. Mohammed, T. Gorton, and Z. F. Dembek. (1999):** Detection and reporting of organism producing extended-spectrum β -lactamase: survey of laboratories in Connecticut. *J. Clin. Microbiol.* 37:4065-4070.
- Tenover, F. C., M. J. Mohammed. J. Stelling, T. O'Brien, and R. Williams. (2001):** Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing. *J. Clin. Microbiol.* 39:241-250.
- Thacker SB, Addiss DG, Goodman RA, Holloway BR, Spencer HC (1992):** Infectious diseases and injuries in child day care: opportunities for healthier children. *JAMA.* 268: 1720-1726.
- Tham, T. N., C. Mabilat, P. Courvalin, and J.-L. Guesdon. (1990):** Biotinylated oligonucleotide probes for the detection and characterization of TEM-type extended-spectrum β -lactamase in Enterobacteriaceae. *FEMS Microbiol. Lett.* 69:109-116.
- Thomson CJ, & Amyes SGR. TRC (1992):** Emergence of clavulanic acid resistant TEM β -lactamas in a clinical strain. *FEMS Microbiol Lett.* 70:113-117.
- Thomson KS, Moland ES. (2001):** Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum β -lactamase-producing Enterobacteriaceae. *Antimicrob Agents Chemother.* 45:3548–3554.

- Thomson, K. S., C. C. and Moland. (1999):** Use of microdilution panels with and without β -lactamases inhibitors as a phenotypic test for β -lactamases production among *Escherichia coli*, *Klebsiella* spp., *Enterobacter* spp., *Citrobacter freundii*, and *Serratia marcescens*. Antimicrob Agents Chemother. 43:1393-1400.
- Thore, M., K. Jalakas, I. Eriksson, and K. Dornbusch. (1989):** Evaluation of a disk approximation test of inducible β -lactamases in Enterobacteriaceae and *Pseudomonas aeruginosa*. APMIS 97:317-324.
- Thornsberry C, Brown SD, & Yee YC, (1993):** Increasing penicillin resistance in *Streptococcus pneumoniae* in the U.S. Infect Med. Suppl/December:15-24.
- Tilton, D. (2002):** Nosocomial Infections: Diseases From Within Our Doors. Retrieved December 2002, 2004.
- Tomasz A. (1994):** Multiple-antibiotic-resistant pathogenic bacteria: a report on the Rockefeller University Workshop. N Engl J Med. 330:1274-1251.
- Tortora, G.J.; Funke, B.R. and Case. C.L. (1995):** Microbiology. An Introduction. Fifth Edition. The Benjamin/Cummings Publishing, Co., Inc., Redwood City, CA. PP.373-382.
- Tzelepi, E., P. Giakkoupi, D. Sofianou, V. Loukova, A. Kermeroglou, and A. Tsakris. (2000):** Detection of extended-spectrum β -lactamases in clinical isolates of *Enterobacter cloacae* and *Enterobacter aerogenes*. J. Clin. Microbiol. 38:542-546.
- Tzouvelekis, L. S., and R. A. Bonomo. (1999):** SHV-type β -lactamases. Curr. Pharm.Des. 5:847-864.

- Tzouvelekis, L. S., E. Tzelepi, P. T. Tassios, and N. J. Legakis. (2000):** CTX-M-type β -lactamases: an emerging group of extended-spectrum enzymes. *Int. J. Antimicrob. Agents*: 14:137-143.
- Tzouvelekis, L. S., M. Gazouli, A. Markogiannakis, E. Paraskaki, N. J. Legakis, and E. Tzelepi. (1998):** Emergence of resistance to third-generation cephalosporins amongst *Salmonella typhimurium* isolates in Greece: report of the first three cases. *J. Antimicrob. Chemother.* 42:273-275.
- Urban, C., K. S. Meyer, N. Mariano, J. J. Rahal, R. Flamm, B. A. Rasmussen, and K. Bush. (1994):** Identification of TEM-26 β -lactamase responsible for a major outbreak of ceftazidime-resistant *Klebsiella pneumoniae*. *Antimicrob Agents Chemother.* 38:392-395.
- Uttley AHC, Collins CH, Naidoo J, George RC. (1988):** Vacomycin resistant enterococci. *Lancet.* 1:57-58.
- Vahaboglu, H., R. Ozturk, H. Akbal, S. Saribas, O. Tansel, and F. Coskunkan. (1998):** Practical approach for detection and identification of OXA-10-derived ceftazidime-hydrolyzing extended-spectrum β -lactamase. *J. Clin. Microbiol.* 36:827-829.
- Vahaboglu, H., R. öztürz, G. Aygün, F. Coskunkan, A. yaman, A. Kaygusuz, H. Leblebicioglu, I. Balik, K. Aydin, and M. Otkun. (1997):** Wide-spread detection of PER-1-type extended-spectrum β -lactamases among nosocomial *Acinetobacter* and *pseudomonas aeruginosa* isolates in Turkey: a nationwide multicenter study. *Antimicrob Agents Chemother.* 41;2265-2269.
- Vahaboglu, H., S. Dodanlı, C Eroglu. R. öztürz, G. Soyletir, I. Yildirim, and V. Avkan. (1996):** Characterization of multiple-antibiotic-resistant *Salmonella typhimurium* Strains: molecular

epidemiology of PER-1 producing isolates and evidence for nosocomial plasmid exchange by a clone. Clin. Microbiol. 34:2942-2946.

Vercauteren, E., P. Descheemaeker, M. Leven, C. C. Sanders, and H. Goosens. (1997): Comparison of screening methods for the detection of extended-spectrum β -lactamases and their prevalence among blood isolates of *Escherichia coli* and *Klebsiella spp.* in a Belgian teaching hospital . J. Clin. Microbiol. 35:2191-2197.

Vila, J., M. Navia, J. Ruiz, and C. Casals . (1997): Cloning and nucleotide sequence analysis of a gene encoding an OXA-derived β -lactamase in *Acinetobacter baumannii*. Antimicrob Agents. Chemother. 41:2757-2759.

Wallace,R.J.,Jr.,V.A. Silcox, M. Tsukamura, B.A. Brown, J. O. Kilburn, W.R. Butler, and G. Onyi. (1993): Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates *Mycobacterium chelonae* -like organism. J.Clin. Microbiol.3:3231-3239.

Walsh CT. (1993): Vancomycin resistance: decoding the molecular logic. Science. 261: 308-309.

Ward JI, Moellering RC Jr (1981): Susceptibility of pneumococci to 14 β -lactam agents: comparison of resistant, intermediate-resistant, and susceptible strains to penicillin. Antimicrob Agents Chemother. 20:204-207.

Weigel L M, Clewell DB, Gill SR, Clark NC, Mc Dougal LK, Flannagan SE., (2003): Genetic analysis of a high-level vancomycin-resistant isolates of *Staphylococcus aureus*. Science; 302:1569-1571.

- Wienerr, J., J. P. Quinn, P. A. Bradford, R.V. Goering, C. Nathan, K. Bush, and R. A. Weinstein. (1999):** Multiple antibiotic-resistant *Klebsiella pneumoniae* and *Escherichia coli* in nursing homes. JAMA 281:517-523.
- Willey BM, Kreiswirth BN, Simor AE, et al., (1993):** Identification and characterization of multiple species of vancomycin- resistance enterococci, including an evaluation of Vitek software version 7.1. J Clin Microbiol. 31:2777-2779.
- Yagi, T., H. Kruokawa, N. Shibata, K. Shibayama, and Y. Arakawa. (2000):** A preliminary survey of extended-spectrum β -lactamase (ESBLs) in clinical isolated of *Klebsiella pneumoniae* and *Escherichia coli* in Japan. FEMS Microbiol. Lett. 184:53-56.
- Yan, J.-J., S.-M. Wu, S.-H. Tsai, J.-J. Wu, and I.-J. Su. (2000):** Prevalence of SHV-12 among clinical isolates of *Klebsiella pneumoniae* producing extended-spectrum β -lactamases and identification of a novel AmpC enzyme (CMY-8) in southern Taiwan. Antimicrob Agents Chemother. 44:1438-1442.
- Yang, Y., Bhachech, P. A. Bradford, B. D. Jett, D. F. Sahm, and K. Bush. (1998):** Ceftazidime-resistant *Klebsiella pneumoniae* and *E.coli* isolates producing TEM-10 and TEM-43 from St. Louis. Antimicrob Agents Chemother. 42:1671-1676.
- Yong, D., R. Park, J. Yum, K. Lee, E. Choi, and Y. Chong (2002):** Further modification of the Hodge test to screen AmpC beta-lactamase (CMY-1)-producing strains of *Escherichia coli* and *Klebsiella pneumoniae*. J. Microbiol. Methods 51:407.

- Yuan, M., H. Aucken, L. M. C. Hall, T. L. Pitt, and D. M. Livermore.**
(1998): Epidemiology typing of *Kebsiellae* with extended-spectrum β -lactamases from European intensive care unit. *J. Antimicrob Agents Chemother.* 41:527-539.
- Zerovs MJ, Kauffman CA, Therasse PM, Bergman AG, Mikesell TS, Schaberg DR. (1987):** Nosocomial infection by gentamicin-resistant *Streptococcus faccalis*: an epidemiologic study . *Ann Intern Med.* 106:687-691.